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Abstract
 
The biological functions of immunoglobulin (Ig)A antibodies depend primarily on their inter-
action with cell surface receptors. Four IgA receptors are presently characterized. The Fc
 
 
 
RI
(CD89) expressed by myeloid cells selectively binds IgA1 and IgA2 antibodies, whereas the
poly-IgR, Fc
 
 
 
/
 
 
 
R, and asialoglycoprotein receptors bind other ligands in addition to IgA. IgA
binding by mesangial cells, epithelial cells, and proliferating lymphocytes is also well docu-
mented, but the nature of the IgA receptors on these cells remains elusive. A monoclonal anti-
body (A24) is described here that specifically blocks IgA binding to epithelial and B lympho-
cyte cell lines. Both the A24 antibody and IgA1 myelomas bind a cell surface protein that is
identified as the transferrin receptor (CD71). The transferrin receptor selectively binds IgA1
antibodies, monomeric better than polymeric forms, and the IgA1 binding is inhibitable by
transferrin. Transferrin receptor expression is upregulated on cultured mesangial cells as well as
on glomerular mesangial cells in patients with IgA nephropathy. The characterization of trans-
ferrin receptor as a novel IgA1 receptor on renal mesangial cells suggests its potential involve-
ment in the pathogenesis of IgA nephropathy.
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Introduction
 
IgA Abs constitute the second most abundant class of Abs
in the systemic circulation and the major Ig class at the mu-
cosal surfaces (1). IgA-producing plasma cells in many hu-
man tissues, such as the bone marrow, produce IgA1 in a
monomeric form that constitutes the predominant type of
IgA in serum. In contrast, a predominance of IgA2-pro-
ducing plasma cells in the mucosal compartment accounts
for the IgA2 predominance in external secretions. Secre-
tory IgA (SIgA),
 
*
 
 composed of IgA1 and IgA2 polymers
which also contain the J chain (1), is transported across epi-
thelial cells into mucosal secretions. The importance of
SIgA in host defense is well established, but the functions
of serum IgA Abs are still incompletely understood (2).
Most of the known IgA Ab-mediated functions require
an interaction with the IgA receptors, four of which have
been identified in humans. These include the IgA Fc re-
ceptor (Fc
 
 
 
RI; CD89) that is expressed on myeloid cells,
including monocyte/macrophages, neutrophils, eosino-
phils, and dendritic cells (3–6), the polymeric-Ig receptor
(poly-IgR) that transports polymeric IgA (and IgM) across
mucosal epithelial cells (7), the Fc
 
 
 
/
 
 
 
R on B cells and
macrophages that also binds both IgA and IgM (8), and the
hepatocyte asialoglycoprotein receptor (ASGP-R) that
binds IgA via its O-linked moieties in addition to asialogly-
coprotein (9).
IgA binding that may not involve the previously defined
receptors has been described on human mesangial cells (10–
14), epithelial cells (15), and dividing T and B lymphocytes
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(16, 17). Mesangial region deposition of IgA1 and IgA1-
immune complexes is the distinguishing characteristic of pri-
mary IgA nephropathy (IgAN [18, 19]). The IgA1 deposits
in IgAN are attributed to the expression of an IgA receptor,
but the molecular nature and function of this receptor re-
main unknown. In this study, we used an mAb that selec-
tively inhibits IgA1 binding to characterize a candidate IgA1-
binding molecule as a dimer of 90-kD chains. This molecule
surprisingly proved to be the transferrin receptor (TfR or
CD71) in experiments that indicate the TfR selectively
binds IgA1 Abs, preferentially in monomeric form. Other
studies using primary cell cultures indicate that the TfR is re-
sponsible for the IgA1 binding to mesangial cells and an im-
munohistochemical analysis indicates that TfR expression is
upregulated in the renal mesangium in patients with IgAN.
 
Materials and Methods
 
Subjects.
 
Renal biopsy tissues from five brazilian patients
(three males and two females) with a clinical and renal immuno-
pathologic diagnosis of primary IgAN were studied. They were
symptomatic for more than 1 yr with hematuria and mild pro-
teinuria. IgAN was diagnosed on immunofluorescence analysis by
the presence of predominant IgA1 deposits in the glomerular mes-
angium associated with focal or diffuse mesangial cell prolifera-
tion. Normal kidney tissue was obtained from an intact pole of
kidney removed for a circumscribed tumor. In each instance, in-
formed consent was obtained from the donors for the use of tissue
samples for experimental purposes.
 
Abs and Reagents.
 
mAbs specific for the Fc
 
 
 
RI included the
A3, A59, A62, and A77 (all 
 
 
 
1
 
 
 
) mAbs (20) and the My43 (
 
  
 
),
which was provided by Dr. L. Shen (Dartmouth Medical School,
Lebanon, NH; reference 21). A panel of anti-TfR (CD71) mAbs
was purchased, including OKT9 (Ortho Diagnostic Systems Inc.),
YJD1.2.2 (
 
 
 
1
 
 
 
; Immunotech/Beckman Coulter), M-A712 (
 
 
 
2a
 
 
 
;
BD PharMingen), and DF1513 (
 
 
 
1
 
 
 
; Sigma-Aldrich). Control
Abs included mouse IgG1
 
 
 
 and IgG2a mAbs of irrelevant specific-
ity (Becton Dickinson). Human myeloma IgA1 proteins (001,
Ret, Dou, and Via) and F(ab
 
 
 
)
 
2
 
 fragments of goat anti-Id 001 Abs
were prepared as described (22). Monomeric and polymeric frac-
tions of IgA1
 
 
 
 (mIgA1 and pIgA1) were separated by gel filtration
on Sephacryl S300 columns (Amersham Pharmacia Biotech;
 
 
 
98% pure) and biotinylated as described (22). Human serum IgG
was purified by ammonium sulfate precipitation and DEAE ion
exchange chromatography (20). Human SIgA was purified from
defatted colostrum by affinity chromatography on CNBr-
Sepharose-4B bound to goat anti–human IgA as described (23).
SIgA contained both IgA1 and IgA2 molecules as evaluated by
ELISA using anti-IgA1 and anti-IgA2 mAbs (18). Unconjugated
goat polyclonal Abs specific for mouse Ig and human IgA were
purchased from Southern Biotechnology Associates, Inc. and ex-
tensively adsorbed with human monoclonal Ig as described (22).
IgA2
 
 
 
 (IgA2m(2); Fel) was provided by Dr. J. Mestecky (Univer-
sity of Alabama at Birmingham; reference 24). A second IgA2
 
 
 
(IgA2m(2); Bel) was a gift from Dr. P. Aucouturier (Necker Hos-
pital, Paris, France; reference 24). Apo and holo forms of Tf were
purchased from GIBCO BRL and Sigma-Aldrich, respectively.
Proteins were quantified by the BCA method according to the
manufacturer’s instructions (Pierce Chemical Co.).
 
Generation of the A24 mAb.
 
A24 (
 
 
 
2b
 
 
 
) was produced as de-
scribed previously (20). Briefly, a Balb/c mouse was hyperimmu-
nized with IgA-binding proteins derived from U937 cells before
the fusion of regional lymph node cells with the Ag8.653 mouse
myeloma cell line. The supernatants were screened for Ab activ-
ity by immunofluorescence and immunoprecipitation assays.
 
Cells.
 
Human mesangial cells were isolated as described pre-
viously (25) from the cortex of normal human cadaver kidneys
unsuitable for kidney transplantation. Briefly, intact glomeruli
were collected from cortical homogenates by serial sieving. The
isolated glomeruli were digested with collagenase (type IV, 750
U/ml; Roche) and then seeded in culture flasks. After the out-
growth of mesangial cells, the glomeruli were removed by wash-
ing and the cells were cultured in RPMI 1640, supplemented
with glutamine (2 mmol/liter), 5 
 
 
 
g/ml insulin, 20% FCS (Life
Technologies), 7 mM glucose, 50 U/ml penicillin, and 50 
 
 
 
g/ml
streptomycin in an atmosphere of 7% CO
 
2
 
. Cells were passaged
using 0.25% trypsin and 0.5% ethylenediaminetetra-acetic acid.
The glomerular mesangial cells were stellate or fusiform in ap-
pearance, grew in multilayers, and stained for 
 
 
 
-smooth muscle
actin and myosin by direct immunofluorescence. These cells
were negative for cytokeratin, factor VIII, and common leuko-
cyte antigen, excluding contamination of epithelial cells, endo-
thelial cells, lymphocytes/monocytes, and fibroblasts. Studies
were performed between passages 4 to 7, when the cells retained
all of the morphologic and immunofluorescent features described
above. Established cell lines included U937, Daudi, Jurkat, and
HT29 that were obtained from American Type Culture Collec-
tion. Cells were stimulated with PMA (50 ng/ml) over a 18-h
period in some experiments.
 
Expression of Human TfR in Chicken Embryo Fibroblasts.
 
Cells
were obtained from SPAFAS as primary chicken embryo fibro-
blasts (CEFs; c/o Line 22) and grown in DMEM supplemented
with 1% chicken serum and 1% FCS, 2% (vol/vol) tryptose phos-
phate broth, 2 mM 
 
l
 
-glutamine, penicillin, and streptomycin.
CEFs were transfected with 30 
 
 
 
g of retroviral construct DNA/
10-cm tissue culture plate of 40% confluent cells using the poly-
brene-dimethyl sulfoxide method (26). Stable expression of wild-
type TfR was achieved using a helper-independent retroviral vec-
tor, BH-RCAS, derived from the Rous sarcoma virus (27). 1–2
wk after transfection, the CEFs stably expressed wild-type TfR on
their surface as a result of infection by recombinant virus (28). 
 
Immunofluorescence Analysis.
 
Cells (0.5 
 
 
 
 10
 
6
 
) were preincu-
bated with 10 
 
 
 
l of human IgG (10 mg/ml) for 15 min on ice to
mask Fc
 
 
 
R before incubation with 10 
 
 
 
l of test mAb (0.1 mg/ml)
for 30 min at 0
 
 
 
C in PBS containing 1% BSA and 0.1% sodium
azide. After two washes, FITC-labeled goat Abs to mouse Ig (0.1
mg/ml) were used as the developing reagent. IgA binding was ex-
amined using an indirect immunofluorescence assay in which cells
preincubated with human IgG were incubated with 10 
 
 
 
l of bi-
otin-labeled IgA (0.2 mg/ml) for 1 h on ice before washing and
incubation with the PE-labeled streptavidin (Southern Biotech-
nology Associates, Inc.) developing reagent (22). For inhibition
studies, cells were preincubated with A24 (1 to 0.01 mg/ml) or
My43 (200 
 
 
 
l hybridoma culture supernantant) for 30 min prior
to biotinylated IgA addition. Immunofluorescent cells were ana-
lyzed by flow cytometry (FACSCalibur™; Becton Dickinson).
 
Cell Surface Iodination, Immunoprecipitation, and Immunoblotting.
 
Viable cells (3 
 
 
 
 10
 
7
 
) were surface labeled with Na
 
125
 
I (1 mCi;
Amersham Pharmacia Biotech) by the lactoperoxidase method.
After washing, cells were lysed in 0.5% NP-40 in PBS containing
protease inhibitors as described previously (3). To deplete Fc
 
 
 
R,
cell lysates were precleared seven times with human IgG-coupled
Sepharose 4B beads (20 
 
 
 
g). For detection of IgA-binding mole-
cules, absorbed lysates were incubated with IgA coupled to 
419
 
Moura et al.
Sepharose 4B beads, or with 10 
 
 
 
g of pIgA1
 
 
 
 plus 20 
 
 
 
l of
Sepharose 4B coupled with F(ab
 
 
 
)
 
2
 
 anti-Id Ab for 2 h at 4
 
 
 
C (3).
For immunoprecipitation of the CD71 and CD89 proteins, ab-
sorbed lysates were incubated with the corresponding mAb (5
 
 
 
g) plus 5 
 
 
 
l of goat anti–mouse Ig-coupled beads (2 mg/ml) for
2 h at 4
 
 
 
C. Proteins were resolved by SDS-10% PAGE analysis.
For immunoblotting, the immunoadsorbed proteins were sepa-
rated by SDS-PAGE and electrophoretically transferred onto a
nitrocellulose Hybond-C (Amersham Pharmacia Biotech) filter at
30 mA for 18–20 h. Blots were incubated in blocking buffer (25
mM Tris-HCl, pH 7.4, 137 mM NaCl, 2.7 mM KCl containing
3% BSA, and 0.1% Tween 20) and then incubated with an anti-
CD71 mAb (0.4 
 
 
 
g/ml) for 2 h at room temperature. Horserad-
ish peroxidase (HRP)-conjugated goat anti–mouse IgG was used
as the developing reagent. Filters were assessed using the en-
hanced chemiluminescence detection system (ECL; Amersham
Pharmacia Biotech).
 
Immunohistochemistry.
 
Frozen 3–4-
 
 
 
m tissue sections were
adhered to microscope slides, fixed in acetone for 10 min at 4
 
 
 
C,
and then allowed to air-dry for at least 1 h. Slides were washed in
PBS before the avidin/biotin blocking steps. Slides were loaded
with normal horse serum (Vector Laboratories) for 30 min to
block nonspecific sites, before incubation with the primary Ab
(mouse mAb) for 60 min in a humid chamber (Vector Laborato-
ries) followed by addition of the biotinylated anti–mouse Ig (Jack-
son ImmunoResearch Laboratories), then the avidin/biotin-alka-
line phosphatase complex (ABC-AP reagent; Vector Laboratories)
and, finally, the substrate. Hematoxylin (1 min) and blueing steps
were then completed before microscopic assessment.
 
Results
 
Identification of a Novel IgA Receptor.
 
The U937 mono-
cytoid cell line has been used previously to identify the Fc
 
 
 
receptor I (CD89; reference 3). To identify other possible
IgA1 binding molecules, the U937 cells were iodinated, sol-
ubilized in NP-40 buffer, and the cell lysates adsorbed with
mIgA1 directly coupled to Sepharose beads. This led to the
identification under reducing SDS-PAGE conditions of a
90-kD cell surface protein in addition to the 55–75-kD
Fc
 
 
 
RI (Fig. 1 A). No binding was observed with control
IgG-coupled beads. The amount of 90-kD IgA-binding
protein was less when it was harvested by adsorption to
pIgA1
 
 
 
 complexed to anti-Id Abs (Fig. 1 B), whereas the
Fc
 
 
 
RI/CD89 molecules harvested by this method were in-
creased as expected (3, 20). Anti-CD89, anti-Id, and irrele-
vant IgG mAbs did not bind the 90-kD protein (Fig. 1 B).
Immunoadsorption assays using the Daudi B cell line, which
Figure 1. Identification of a novel IgA1
receptor. (A) Monomeric (m) IgA1 (001)-
coupled beads precipitates a 90-kD protein
from  125I-radiolabeled U937 cells solubi-
lized with 0.5% NP-40. Fc R-cleared cell
lysates were incubated with IgG- or IgA1
beads and the eluates were analyzed by SDS-
10% PAGE under reducing conditions be-
fore analysis by autoradiography. (B) The
90-kD protein also binds polymeric (p) IgA1
and is expressed both by U937 monocytoid
cells and Daudi B cells. Cell surface proteins
(125I radiolabeled) were immunoprecipitated
from cell lysates by either anti-CD89 (A62
and A59) mAbs or by pIgA1 (001) plus
F(ab )2 fragments of anti-Id 001 (co) coupled
to beads before analysis on SDS-10% PAGE
under reducing conditions. (C) Comparative
immunofluorescence analyses of mIgA1,
pIgA1, and secretory (S) IgA (IgA1/IgA2
mixture) binding to Daudi cells. The IgA
preparations were biotinylated and PE-con-
jugated streptavidin was used as the develop-
ing reagent. (D) IgA1 binding is concentra-
tion dependent. Daudi cells were incubated
with twofold serial dilutions of biotinylated
mIgA1 or pIgA1 followed by PE-conjugated
streptavidin. Mean fluorescence intensities
(MFI) of mIgA1 or pIgA1 were plotted after
subtracting values of each corresponding
concentration of biotinylated IgG. (E) Fail-
ures of IgA2 (Bel) to bind to Daudi cells. 
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does not express CD89, indicated that the 90-kD protein is
the major IgA receptor on these cells (Fig. 1 B, right). Un-
der the same conditions, we could not detect the recently
described 70-kD Fc
 
 
 
/
 
 
 
R (8). As Daudi cells primarily ex-
press the 90-kD IgA1 receptor, we used these to compare
the binding of different IgA forms and complexes. In an im-
munofluorescence analysis, mIgA1 was found to bind more
efficiently to Daudi cells than did pIgA1 and SIgA Abs (Fig.
1 C). The mIgA1 binding was concentration dependent
with maximal labeling intensity at concentrations of 1 mg/
ml, whereas saturation was not evident with pIgA1 (Fig. 1
D). Remarkably, IgA2 binding was not observed (Fig. 1 E).
 
Characterization of the 90-kD IgA1-binding Protein as TfR.
 
In an initial attempt to determine the molecular nature of
the 90-kD IgA1-binding molecule, we employed the A24
mAb that was generated against IgA-binding proteins derived
from U937 cells. The A24 mAb was found to specifically
recognize the 90-kD IgA1-binding molecule expressed on
the U937 cell surface (Fig. 2 A, lane 4). Immunodepletion
experiments indicated that 90-kD protein has no apparent
physical association with the previously defined CD89
Fc
 
 
 
RI (Fig. 2 A). Like the IgA1-binding molecule (data
not shown), the A24-binding molecule migrated as a 180-kD
homodimer under nonreducing conditions (Fig. 2 B). As
these results suggested the transferrin receptor (TfR/
CD71) as a candidate for the novel IgA1 receptor, we ex-
amined the reactivity of known anti-TfR (CD71) mAbs
with the 90-kD cell surface protein isolated on the basis of
its binding to either IgA1 or the A24 mAb (Fig. 2 C). The
90-kD molecules on Daudi B cells that were bound by
mIgA1 and the A24 mAb were recognized by the
YDJ1.2.2 anti-CD71 mAb, thereby identifying these as
components of the TfR. Notably, an IgA2
 
 
 
 (Fel) myeloma
did not bind the TfR. Another anti-TfR mAb, OKT9
(O9), also depleted the A24-binding protein from U937
lysates, thereby confirming that the A24 mAb recognizes
the TfR (Fig. 2 D).
To verify the identity of the new IgA-R as the TfR, we
took advantage of the fact that chicken TfR displays only
53% homology with the human TfR extracellular domain
(29). Accordingly, CEFs did not bind human IgA1,
whereas human IgA1 was bound by CEF transfectants ex-
pressing the human TfR as well as by the Jurkat human T
cell line used as positive control (Fig. 3). The TfR expres-
sion was monitored in these experiments by staining with
the A24 anti-TfR mAb.
To exclude the possibility that the IgA1 binding to TfR
was mediated by transferrin, we cultured Daudi and Jurkat
cells in RPMI in the presence or absence of 10% FCS for 1 h
before incubation with IgA1. Cells cultured in serum free
media bound more IgA1 than cells cultured with FCS,
thereby indicating that Tf does not mediate the interaction
between TfR and IgA1, but rather may inhibit the IgA1
binding (data not shown).
To determine whether the A24 mAb recognizes the TfR
on primary hematopoietic cells, we examined its immuno-
fluorescence reactivity with immature hematopoietic cells in
fetal liver and bone marrow samples. As anticipated, the A24
mAb decorated the surface of mononuclear hematopoietic
cells (
 
 
 
60%) in these hematopoietic tissues, whereas the A24
mAb did not stain the nondividing populations of mononu-
clear and polymorphonuclear cells in adult blood samples.
Figure 2. Characterization of the IgA1
receptor as the TfR. (A) Immunodepletion
experiments indicate that the 90-kD and
CD89 IgA binding molecules are nonasso-
ciated proteins, and that the A24 mAb rec-
ognizes the 90-kD I-IgA-binding protein.
NP-40 solubilized 125I-surface proteins were
adsorbed with either anti-CD89 (A59 ads)
or A24 (A24 ads) before isolation on A24-
or IgA1-coupled Sepharose beads and anal-
ysis of the eluates on SDS-10% PAGE un-
der reducing conditions. (B) The A24 mAb
recognizes a 180-kD dimeric molecule.
Surface proteins (125I radiolabeled) from cell
lysates were immunoprecipitated by A24 or
an irrelevant IgG1  plus goat anti–mouse
Ig-coupled beads, and analyzed by 5 to 15%
SDS-PAGE under reducing (R) and nonre-
ducing (NR) conditions. (C) Anti-CD71
immunoblotting identifies the IgA1 recep-
tor as TfR. Proteins adsorbed from cell ly-
sates by immobilized IgA1 (Ret), IgA2
(Fel), A24 mAb, the YDJ1.2.2 mAb, were
analyzed by immunoblotting with the
YDJ1.2.2 anti-CD71 (YDJ) mAb plus
HRP-conjugated goat anti–mouse Ig and
developed by enhanced chemilumines-
cence method. (D) Immunodepletion of the
90-kD IgA1 binding protein by the anti-
CD71 OKT9 (O9) mAb confirms the TfR
nature of the A24 reactive protein. 
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The A24 mAb and Tf Block the IgA1 Binding to TfR.
 
To
further characterize the IgA1-binding specificity of TfR,
Daudi cells were preincubated with either the A24 mAb or
Tf as inhibitors. The A24 mAb inhibited mIgA1 binding in
a dose-dependent manner, reaching 
 
 
 
90% inhibition at an
A24 concentration of 1 mg/ml, whereas the A62 anti-
CD89 FcR mAb had no effect (Fig. 4 A); My43 had no ef-
fect as well (data not shown). Similar results were obtained
with two additional myeloma IgA1
 
 
 
 monomeric proteins
(001 and Via; data not shown). Competition assays were
also performed using three commercially available anti-
CD71 mAb and our A24 mAb. The A24 was the only
anti-TfR mAb tested that significantly inhibited mIgA1
binding by the Daudi B cells in this assessment (Fig. 4 B).
To determine whether IgA1 binding competed with the
Tf-binding sites of TfR, we preincubated cells with puri-
fied transferrin before the addition of mIgA1 (Fig. 4 C).
The apo and holo forms of Tf (unsaturated or Fe
 
2
 
 
 
-satu-
rated, respectively) were used in these experiments. A
dose-dependent inhibition was obtained with the holo Tf,
thereby confirming the specificity of the IgA–TfR interac-
tion and suggesting that the IgA1 binding site is located in
the proximity of the Tf binding site on TfR. A lower level
of inhibition was observed with the Fe
 
2
 
 
 
 unsaturated apo
form of Tf (43% maximal inhibition; data not shown).
 
Inversely Regulated TfR and CD89 Expression during Cellular
Differentiation Correlates with Differential Monomeric and Poly-
meric IgA1 Binding. 
 
It has been previously demonstrated
that PMA treatment induces TfR downregulation (30) in
parallel with upregulation of CD89 expression (3). We
therefore used IgA binding cell lines that do or do not ex-
press CD89 (Fc
 
 
 
RI) to evaluate the binding properties of
polymeric and monomeric IgA1 to TfR and CD89, before
and after the induction of cellular differentiation by PMA
treatment. The monocytic cell line, U937, that expresses
low levels of CD89 under unstimulated conditions, bound
mIgA1 better than pIgA1 and the IgA1 binding was effi-
Figure 3. Identification of the TfR as an IgA1 receptor. Immunofluo-
rescence analysis of CEFs either lacking or expressing the human TfR and
Jurkat T cells was performed using monomeric IgA1 (thin line) and A24
mAb (heavy line). Cells preincubated with human IgG to mask Fc R
were labeled with biotinylated human IgA1 or A24 followed by incuba-
tion with PE-conjugated streptavidin as a developing reagent. Biotiny-
lated human IgG was used as a negative control of binding (dashed line).
Figure 4. Immunofluorescence analysis of the ability of the A24 mAb
and transferrin to block IgA1 binding by TfR on Daudi B cells. In each
panel the heavy dark line indicates the uninhibited IgA1 binding histo-
gram. (A) A24 mAb blocks IgA1 (Ret) binding to Daudi cells in a dose-
dependent manner. (B) The anti-CD71 mAbs, YDJ1.2.2, DF1513, and
M-A712, are inefficient inhibitors of IgA binding ( 30% inhibition at
0.1 mg/ml concentration). (C) Holo-Tf blocks the IgA1–TfR interac-
tion in a dose-dependent manner. Top right panels indicate the percent
inhibition of mIgA1 binding by the anti-CD71 mAb and by holo-Tf
(mean   SD; n   6). 
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ciently inhibited by the A24 anti-TfR mAb ( 80% inhibi-
tion), whereas minimal inhibition ( 10%) was observed
with the My43 anti-CD89 mAb that blocks the IgA bind-
ing site of Fc RI/CD89 (Fig. 4). PMA-induced differenti-
ation of U937 cells resulted in diminished TfR expression
and mIgA1 binding that was inhibitable by the A24 anti-
TfR mAb. On the other hand, the PMA-induced mono-
cyte/macrophage differentiation led to enhanced CD89
expression and enhanced pIgA1 binding that was specifi-
cally blocked by the My43 Ab ( 70%; Fig. 5). By contrast,
the HT29 epithelial cell line (15), which does not express
CD89 even after PMA treatment, bound mIgA1 much
more efficiently than pIgA1 (Fig. 5), and the A24 anti-TfR
mAb inhibited the IgA1 binding, therefore confirming that
TfR mediates this mIgA1 binding. The correlation ob-
served between the downregulation of TfR expression and
of mIgA1 binding after PMA treatment confirmed that
TfR is the primary IgA1 receptor on the HT29 cells. The
above data also indicate that mIgA1 is preferentially bound
by the TfR, whereas pIgA1 is preferentially bound by
Fc RI/CD89.
IgA1 Binding by Cultured Human Mesangial Cells Is Medi-
ated by the TfR, Which Is Overexpressed in Patients with IgAN.
The presence of an uncharacterized IgA-binding protein
on cultured human mesangial cells has been reported by
several groups of investigators (11–14). We therefore ex-
amined the possibility that the IgA receptor expressed on
cultured mesangial cells could be the TfR. This analysis in-
dicated that A24-reactive protein is indeed expressed on
cultured mesangial cells (Fig. 6 A). In lysates of mesangial
cells, both mIgA1 and A24 identified the 90-kD TfR
chains that are recognized by the YDJ1.2.2 anti-CD71
mAb (Fig. 6 B). Cell surface mIgA1 binding was specifi-
cally inhibited ( 70%) by A24 and by Tf (Fig. 6 C). To
evaluate TfR expression on primary mesangial cells, immu-
nohistochemical staining of kidney tissue sections was per-
formed using the anti-CD71 mAbs. In situ TfR expression
was detected on mesangial cells from patients with IgAN,
but not in normal glomeruli. Fig. 6, D and E, illustrates the
TfR expression in mesangial areas in renal kidney biopsy
tissues from two IgAN patients examined with the OKT-9
and M-A712 anti-CD71 mAbs, and an irrelevant IgG1
mAb as a control. This observation was confirmed in renal
biopsies from three additional IgAN patients (not shown).
These results indicate enhanced TfR expression by mesan-
gial cells in patients with IgAN.
Discussion
The novel IgA1 receptor, characterized in this study as a
disulfide-linked homodimeric molecule of Mr 180,000, was
unexpectedly identified as the transferrin receptor (TfR/
CD71; reference 31). IgA1 represents a third ligand for the
TfR, previously recognized TfR ligands being Tf itself (31)
Figure 5. Comparative analy-
sis of mIgA1 and pIgA1 binding
to TfR and Fc RI (CD89) on
cells that differentially express
these IgA receptors. The IgA
binding specificity of the two
types of receptors, TfR and
Fc RI, was assessed using the
ligand blocking mAbs, A24 and
My43. Cells were stimulated or
not with PMA (10 7 M) for 18 h
before staining with biotinylated
mIgA1 (Ret) or pIgA1 (Ret) and
PE-conjugated streptavidin as
the developing reagent (solid
lines). Biotinylated IgG (dashed
lines) were used as a negative
control. The percent inhibition
of IgA1 binding by the A24 and
My43 mAbs is shown in bar
graph inserts. TfR and CD89
expression were evaluated by bi-
otinylated A24 (heavy line) and
A77 (thin line) in the third col-
umn of panels (numbers indicate
the mean fluorescence intensity).423 Moura et al.
and the hemochromatosis protein (32). Analysis of the
TfR–IgA interaction was facilitated by the observation that
cells of the Daudi B cell line and the HT29 intestinal epi-
thelial cell line express the TfR/CD71 but do not express
the Fc RI/CD89, and that the A24 anti-CD71 mAb
uniquely blocks IgA binding. Using these reagents and
model cell lines, these studies show that TfR selectively
binds IgA1 Abs, whereas the Fc RI binds both IgA1 and
IgA2 Abs. The specificity of the IgA1–TfR interaction was
verified in experiments using CEFs transfected with the
human TfR cDNA. The IgA1 binding by TfR differs from
that of Fc RI in that the TfR preferentially binds mIgA1
over pIgA1 and SIgA. IgA1 binding by these two types of
IgA receptors was also shown to depend on the cellular dif-
ferentiation status. TfR expression was predictably down-
regulated in cells that exit the cell cycle to undergo differ-
entiation. This differential usage of IgA1 receptors was
demonstrated using PMA as an inducer of U937 cell differ-
entiation that results in the upregulation of CD89 and
downregulation of TfR expression (3, 30). In untreated
U937 monocytoid cells, therefore, TfR was the primary
receptor for mIgA1, whereas Fc RI/CD89 was responsi-
ble for most of the pIgA1 binding in PMA-treated U937
cells that undergo macrophage differentiation. Conversely,
in the cell types that do not express the Fc RI, such as the
Daudi B cells and HT29 epithelial cells, the TfR remained
the primary mIgA1 receptor even after PMA treatment.
The remarkably selective TfR affinity for the IgA1 sub-
class of Abs suggests that TfR/IgA1 binding is influenced by
the unique IgA1 hinge region where three to five O-linked
carbohydrates moieties are located, as the primary difference
between IgA1 and IgA2 subclasses is a 13 amino acid dele-
tion in the IgA2 hinge region. The IgA2 Abs consequently
have fewer O-linked glycosylation sites than IgA1 Abs (1, 2),
which could possibly explain the lack of IgA2 binding by
TfR. N-glycans are unlikely to be involved in the IgA1
binding to TfR, as IgA1 Abs have twofold less N-linked
carbohydrate sites in their CH domains than IgA2 Abs. In
this regard, it is noteworthy that N-glycans confer preferen-
tial IgA2 binding to ASGP-R and promote its rapid clear-
ance from the circulation by the liver (33).
The TfR/IgA1 interaction on the HT29 epithelial cell
line provides a reasonable explanation for the ability of
these cells to bind IgA (15). However, it has also been re-
ported that HT29 cells express the polymeric Ig receptor
that binds to polymeric IgA and IgM (34). Nevertheless,
Figure 6. Identification of IgA1 binding by TfR on cultured human mesangial cells and TfR overexpression by mesangial cells in renal biopsies from
IgAN patients. (A) TfR expression by cultured human mesangial cells (5th passage) is identified using the A24 anti-TfR mAb. Immunoprecipitation of
TfR 90-kD chains from the 125I-labeled mesangial cell lysates and analyzed in 10% SDS-PAGE under reducing conditions. (B) mIgA1 (Ret) but not IgA2
(Fel), bind a mesangial cell protein of 90 kD that is recognized by immunoblotting with the YDJ1.2.2 anti-CD71 mAb. Proteins in the cell lysates were
separated by 10% SDS-PAGE under reducing conditions. (C) A24 and Tf blocked biotinylated mIgA1 (Ret) binding to cultured mesangial cells by
 70%. Biotinylated IgG was used as negative control. (D) Detection of TfR in mesangial cell areas in renal biopsy material from a patient with IgAN
(Pat 1), but not in normal renal tissue. Immunohistochemical analysis of TfR expression was performed using the OKT-9 anti-CD71 mAb. (E) Detec-
tion of TfR expression in mesangial cell areas in renal biopsy material from a second patient with IgAN (Pat 2) using the M-A712 anti-CD71 mAb. An
IgG1 (IgG1) mAb of irrelevant specificity was used as negative control.424 Transferrin Receptor Is an IgA1 Receptor
under our conditions, HT29 cells preferentially bind mo-
nomeric IgA1 over polymeric IgA1. TfR expression by
primary epithelial cells has also been described (35), and
our preliminary studies indicate that cryptic epithelial cells
from normal human small intestine are stained by the A24
Ab (unpublished data). In view of the fact that the poly-
IgR cannot bind mIgA, it is also notable that mIgA has
been found in the mucosal and glandular secretions of J
chain–deficient mice (36). It seems reasonable, therefore, to
propose that the TfR–IgA1 interaction on epithelial cells
may provide an alternative pathway for mIgA transport
into the mucosal secretions.
IgAN, also called Berger’s disease, is the most common
form of glomerulonephritis and is a principal cause of renal
failure worldwide. Typical clinical features include haema-
turia and proteinuria. Kidney biopsies obtained from IgAN
patients reveal mesangial deposits of IgA and proliferation
of the glomerular mesangium. These mesangial deposits of
IgA1 and IgA1-immune complexes constitute a diagnostic
hallmark of primary and secondary IgAN in humans (18,
19). Our data point to potential roles for two types of IgA
receptors in the pathogenesis of IgAN. In a previous study
(37) we found that Fc RI may be involved in the devel-
opment of IgAN through the formation of IgA complexes
by shedding of soluble Fc RI  chain complexed with its
IgA Ab ligand. This possibility was supported by the find-
ing that transgenic mice expressing human Fc RI sponta-
neously develop IgAN which is dependent on the presence
of IgA. It has also been suggested that the glomerular IgA1
deposition in these disorders could be mediated via a spe-
cific IgA receptor on mesangial cells (10–14). However,
this possibility has not been confirmed in efforts to demon-
strate Fc RI expression by human mesangial cells using
anti-CD89 Abs (11–14, 38). The results of this study in-
stead indicate that cultured human mesangial cells express
TfR as the primary IgA1 cell surface receptor. Moreover,
our immunohistochemical analysis indicates that glomeru-
lar mesangial cell expression of TfR is consistently en-
hanced in patients with IgAN. The proliferative state of
the mesangial cells in IgAN patients theoretically could ac-
count for the enhanced TfR expression. Alternatively, the
IgA1 Ab deposition could enhance mesangial cell prolifer-
ation (39). Although it is presently unclear which of these
constitutes the primary event, our observations suggest that
the upregulation of TfR expression on mesangial cells
could explain the selective mesangial IgA1 deposition in
patients with IgAN. The ability of TfR to bind pIgA1, al-
beit less well than mIgA1, is also consistent with the depo-
sition of both polymeric and monomeric forms of IgA1
observed in renal biopsies from IgAN patients (40). Previ-
ous reports of preferential pIgA1 binding by human
mesangial cells (12–14) are not so easily explained by our
analysis of the TfR/IgA1 binding characteristics. This issue
clearly deserves further study, along with analysis of the in-
fluence that aberrant glycosylation of IgA1 and IgA1-
immune complexes in IgAN patients (41) may have on the
IgA1/TfR interaction. The elucidation of a mesangial
TfR–IgA1 interaction as a basis for mesangial IgA1 deposi-
tion thus opens a new avenue for study of the pathogenesis
and treatment of IgAN.
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